MenHibrix Approval History

• FDA approved: Yes (First approved June 14th, 2012)
• Brand name: MenHibrix
• Generic name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
• Company: GlaxoSmithKline
• Treatment for: Haemophilus influenzae Prophylaxis, Meningococcal Meningitis Prophylaxis

MenHibrix (Hib-MenCY-TT) is a combination vaccine for the active immunization of infants and young children 6 weeks through 18 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).

FDA Approval History for MenHibrix

Date	Article
Jun 15, 2012	GSK Receives FDA Approval for MenHibrix
Dec  1, 2011	Regulatory Update: Glaxosmithkline Submits Additional Information for Candidate Meningococcal and Hib Combination Vaccine
Sep 26, 2011	Regulatory Update: GlaxoSmithKline Receives Complete Response Letter from FDA for MenHibrix meningococcal and Hib combination vaccine

See also...

MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.